- Home
- FYBR vs BBIO Comparison
FYBR vs BBIO Comparison
Compare FYBR & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FYBR
- BBIO
- Stock Information
- Founded
- FYBR 1935
- BBIO 2015
- Country
- FYBR United States
- BBIO United States
- Employees
- FYBR N/A
- BBIO N/A
- Industry
- FYBR Telecommunications Equipment
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- FYBR Consumer Discretionary
- BBIO Health Care
- Exchange
- FYBR Nasdaq
- BBIO Nasdaq
- Market Cap
- FYBR 9.2B
- BBIO 8.8B
- IPO Year
- FYBR N/A
- BBIO 2019
- Fundamental
- Price
- FYBR $36.94
- BBIO $49.08
- Analyst Decision
- FYBR Hold
- BBIO Strong Buy
- Analyst Count
- FYBR 5
- BBIO 16
- Target Price
- FYBR $38.50
- BBIO $61.69
- AVG Volume (30 Days)
- FYBR 2.8M
- BBIO 2.9M
- Earning Date
- FYBR 07-29-2025
- BBIO 08-05-2025
- Dividend Yield
- FYBR N/A
- BBIO N/A
- EPS Growth
- FYBR N/A
- BBIO N/A
- EPS
- FYBR N/A
- BBIO N/A
- Revenue
- FYBR $6,045,000,000.00
- BBIO $235,812,000.00
- Revenue This Year
- FYBR $5.64
- BBIO $106.33
- Revenue Next Year
- FYBR $3.32
- BBIO $54.30
- P/E Ratio
- FYBR N/A
- BBIO N/A
- Revenue Growth
- FYBR 4.15
- BBIO 7.62
- 52 Week Low
- FYBR $27.67
- BBIO $21.72
- 52 Week High
- FYBR $39.21
- BBIO $51.86
- Technical
- Relative Strength Index (RSI)
- FYBR 56.22
- BBIO 55.76
- Support Level
- FYBR $36.85
- BBIO $48.03
- Resistance Level
- FYBR $37.16
- BBIO $51.86
- Average True Range (ATR)
- FYBR 0.16
- BBIO 1.95
- MACD
- FYBR 0.00
- BBIO -0.08
- Stochastic Oscillator
- FYBR 64.57
- BBIO 71.55
About FYBR Frontier Communications Parent Inc.
Frontier Communications Parent Inc is a communications and technology provider offering broadband services. The company provides voice services, including data-based voice over Internet protocol (VoIP) and unified communications as a service (UCaaS), as well as long-distance and voice messaging services, to consumer and business customers in all its markets.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.